Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule protein analysis platform development, has announced its participation in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule protein analysis platform development, has announced its participation in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will engage in a fireside chat on June 10, 2025, at 2:00 p.m. Eastern Time. Investors and interested parties can access both live and archived webcasts of the presentation through the "Investors" section on Nautilus' website at www.nautilus.bio.
Details
News Market Reaction – NAUT
The recorded move for NAUT in the trading session of this news was +5.59%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, May 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the Goldman Sachs 46th Annual Global Healthcare Conference.
Nautilus’ management is scheduled to participate in a fireside chat on Tuesday, June 10, 2025, at 2:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.